Pursuant to Regulation 30 of the Listing Regulations we hereby inform that based on the recommendation of the Audit Committee and the Committee of Independent Directors, the Board of Directors of the Company at its meeting held today, i.e. January 29, 2021 has inter-alia, considered and approved the Scheme of Arrangement ('Scheme') amongst Cipla Limited ('Cipla or Demerged Company'), Cipla BioTec Limited, wholly owned subsidiary of the Company ('CBL or Resulting Company 1') and Cipla Health Limited, wholly owned subsidiary of the Company ('CHL or Resulting Company 2') and their respective members and/or creditors, pursuant to sections 230 to 232 and other relevant provisions of the Companies Act, 2013. Please find enclosed intimation dated 26th October 2021 (As per BSE Announcement Dated on 26/10/2021) Pursuant to the provisions of Regulation 30 of the SEBI Listing Regulations and further to the intimation dated 26th October 2021, we hereby notify that the Board of Directors of Cipla Limited ('the Company') at its meeting held today, i.e., 25th January, 2022 have inter alia, approved the transfer of the following undertakings as a going concern on a slump sale basis in the following manner: (i) India based US business undertaking ('Undertaking 1') to Cipla BioTec Limited, a wholly owned subsidiary of the Company ('Transferee Company 1 or CBL'); and (ii) Consumer business undertaking ('Undertaking 2') to Cipla Health Limited, wholly owned subsidiary of the Company ('Transferee 2 or CHL') as a going concern on a slump sale basis. (As Per BSE Announcement Dated on 25/01/2022)